ABBV: Leadership change

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers On October 28, 2026, Jennifer L. Davis, a Class II director of AbbVie Inc. (“AbbVie”), notified the Company’s Board of Directors (the “Board”), of her intent to resign from the Board, effective November 2, 2026, in light of her recent appointment as Chief Executive Officer at Align Technology, Inc. Her resignation as a director is not the result of any dispute or disagreement with AbbVie on any matter relating to the operations, policies or practices of AbbVie. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: November 2, 2026 By: /s/ Perry C. Siatis Perry C. Siatis Executive Vice President, General Counsel and Secretary